Onco Actu du 30 novembre 2018

	1. Biologie
Inconspicuous protein key to deadly blood cancer [Cold Spring Harbor Lab] ZFP64 is so common within the healthy human body that, until now, researchers haven’t considered it a factor in any type of leukemia. Further testing by the Vakoc team revealed that the creation of MLL fusion protein is entirely dependent on this single, inconspicuous protein.
	1.4 Biologie - Technos
NIH director says there’s work to do on regulating genome editing globally [STAT] While Collins said in a statement issued Wednesday that the revelation of CRISPR babies highlighted the need for a “binding international consensus” on germline gene editing, he acknowledged there is little consensus as to how governments should translate such scientific opinions into law.
Opinion: Don’t Ban the Use of CRISPR in Embryos [The Scientist] Despite a premature and ethically sketchy claim of genome editing in twin girls, an outright prohibition could blunt promising, responsible progress.
	3.1.1 Prévention - Tabac - e-cigs
FDA warns e-cigarette liquid maker against products resembling food for kids [Reuters] Electric Lotus' products outlined in Thursday's warning included "Cereal Treat Loopz", which resembled Lucky Charm products. Many of the products have cartoon characters on their labeling and advertising, the FDA said.
	4.12 Biopsies liquides
Liquid Biopsy Is Effective at Guiding Treatment of Lung Cancer, Study Finds [Memorial Sloan kettering Cancer Center] Among the most important benefits of the liquid biopsy was the quick turnaround time. It took a median of nine days from the time of the blood draw for doctors to get the results of the liquid biopsy. It takes a median of 20 days from the time a tissue specimen arrives in a lab to get results from tumor sequencing.
	4.9 Dép., diag. & prono. - Sein
New Analysis of NSABP Randomized B-20 Study Confirms Patients with Oncotype DX Breast Recurrence Score® Results Greater Than 25 Have Life-saving Benefit from Chemotherapy, Reinforcing the Conclusions of the Landmark TAILORx Study [Genomic Health] Applying the patient criteria from the TAILORx study, the largest ever breast cancer treatment trial, sponsored by the National Cancer Institute (NCI), and led by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), NSABP conducted a new analysis in 569 patients from its previously completed B-20 study. The results show that Oncotype DX® provides definitive information about which patients will derive life-saving benefit from chemotherapy treatment.
	5.1 Traitements - Pré-clinique
Measuring cancer cell “fitness” reveals drug susceptibility [MIT News] “By measuring a cell's mass and growth rate immediately prior to single-cell RNA-sequencing, we can now use a cell’s ‘fitness’ to classify it as responsive or nonresponsive to a drug, and to relate this to underlying molecular pathways.”
	5.10 Traitements - Essais
ASCO and Friends of Cancer Research Applaud NCI’s Expansion of Clinical Trial Eligibility Criteria [ASCO] The protocol template was expanded to help increase the opportunity for participation in NCI-funded clinical trials for patients with certain health care conditions, as well as to provide an opportunity for patients younger than age 18 to participate in adult clinical trials in certain circumstances.
	5.12 Immunothérapies
An interview with Nobel Prize-winning cancer immunologist Jim Allison [BiopharmaDive] I started working on T cells in 1982, and I told myself, "I bet this is going to be a great way to treat cancer." No drug company would have done that. I had to figure out how to get it to work. Translational science is important, but they aren't going to come read the tea leaves. That's what the academic science is for.
The number of I/O cancer drugs in the clinic continues to swell at an explosive pace — offering new hope, fresh concerns [EndPoints] But while all the numbers continue to steam ahead, there has been a significant decline in one key category: patient recruitment has slowed 70% in 4 years, they say. And that underscores a dramatic need to expand the number of patients who can be recruited for current and upcoming drug trials.
	5.12.1 Immunothérapies - partenariats
Cancer Research UK, the Francis Crick Institute and Bristol-Myers Squibb join forces to map out lung cancer immunology [Cancer Research UK] The new £2.4 million research project called RUBICON - a rule book and immune atlas for combination therapy – will map out the immunology of lung cancer in detail. The study will be led by Cancer Research UK’s chief clinician and Francis Crick Institute group leader, Professor Charles Swanton.
	5.12.8 Immunothérapies - Economie
Merck pushes small batch of price hikes, including top-selling Keytruda and Gardasil [FiercePharma] Merck’s latest move to raise list prices comes as Pfizer gets ready to implement 41 of its own increases early next year.
Merck increased list prices on Keytruda, Gardasil in November [BiopharmaDive] Keytruda (pembrolizumab) and Gardasil (HPV 9-valent vaccine, recombinant) combined to net $4.3 billion in U.S. sales through the first nine months, slightly more than one-third of Merck's entire U.S. pharmaceutical sales in that time period.
Immunotherapy drug made available for some NHS patients with advanced skin cancer after surgery [cancer Research UK] The committee also said there was limited information on the overall survival benefits of the nivolumab. Nivolumab will therefore be made available through the Cancer Drugs Fund while more data is collected on its effectiveness.
	5.3 Traitements - FDA, EMA, NICE...
FDA to follow EMA with move from London to Amsterdam [EndPoints] As the FDA now communicates with its European counterparts on a daily basis, the US agency has decided to make the move from London to Amsterdam alongside the EMA.
	5.3.4 Traitements - AMM (FDA, EMA,...)
FDA Approves New Targeted Drug for Leukemia Tested at University of Pennsylvania [Penn Medicine] Drug is the first to target common mutation associated with relapse, short survival in AML.
Astellas’ Xospata wins FDA nod in AML, with Daiichi competition looming [FiercePharma] Xospata might not be alone in the FLT3-mutated relapsed/refractory setting long, though. Fellow Japanese drugmaker Daiichi Sankyo’s FLT3 inhibitor, quizartinib, just won an FDA priority review in FLT3-ITD. Affecting around 25% of AML patients, the ITD form is much more common than the TKD mutation.
	5.4 Traitements - Economie
Targeted cancer drug made available for some NHS liver cancer patients [Cancer Research UK] The National Institute for Health and Care Excellence (NICE) said in March this year that it wasn’t cost-effective to offer regorafenib to all advanced liver cancer patients when surgery isn’t an option. But that decision has now been reviewed following a discount deal between the NHS and the company who makes the drug.
Life extending treatment for patients with advanced liver cancer recommended by NICE [NICE] The drug regorafenib (also called Stivarga and made by Bayer) can now be offered to people with advanced liver cancer if their liver is working well but the diseased area cannot be surgically treated and if they have already taken the life-extending medicine sorafenib.
	5.6 ESMO
ESMO Immuno-Oncology Congress: Where the Community of Stakeholders Meets [ESMO] This Congress, to be held from 13-16 December in Geneva, Switzerland, is designed for basic, translational and clinical researchers, immunologists, oncology clinicians and other stakeholders, and will attractone thousand participants who will benefit from a broad and varied programme as well as focused sessions dedicated to different tumour types and key aspects of this treatment modality.
	5.7.1 SABCS-communiqués
Lilly to Present Clinical Data for Verzenio® (abemaciclib) and Real-World Evidence across HR+, HER2- Metastatic Breast Cancer at 2018 SABCS [Lilly] Presentation of results from nextMONARCH 1 evaluates single-agent activity of Verzenio in heavily pre-treated patients.
	5.8.2 ASH - Pharma
nanoString Technologies Highlights Advances in Precision Oncology at the 60th Annual Meeting of the American Society of Hematology [nanoString] 40+ Abstracts Highlight the Value of the nCounter Platform in Hematology & Immuno-oncology, Including Thirteen that Demonstrate the Potential Utility of the LymphMark Lymphoma Subtyping Test.
Bristol-Myers Squibb to Highlight New Data from Broad Oncology Portfolio at the 60th American Society of Hematology Annual Meeting [BMS] Nineteen presentations and publications featuring data from three Bristol-Myers Squibb medicines, alone and in combination, across four hematologic malignancies.
	6.1 Observation
U.S. life expectancy declines again in sobering ‘wake-up call’ [STAT] In the nation’s 10 leading causes of death, only the cancer death rate fell in 2017. Meanwhile, there were increases in seven others — suicide, stroke, diabetes, Alzheimer’s, flu/pneumonia, chronic lower respiratory diseases and unintentional injuries.
	6.10 Politiques
Beware the rise of the radical right [Nature] Academic freedom is on the hit list when radical politicians gain office — as they have done in Europe.
	6.7.3 DMP
Cultural shift needed to keep trust in use of patient data [Queen Mary University of London] A radical culture change in the NHS, and across the health data and medical technology community, is needed to make sure that the NHS can deliver benefits from patient data, and to retain public trust, says a new report authored by Queen Mary University of London academics.
	6.9 Controverses
Under protest, OSU cancer researcher dogged by misconduct allegations stepping down as department chair [Retraction Watch] Carlo Croce says he’s feeling blindsided after he was told to step down as a department chair in OSU’s College of Medicine. “He told the dean he was not going to step down,” said Croce’s attorney, James Arnold. “He asked for a reason. He wasn’t given any.”